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Abstract
Introduction: Transmembrane protein (TMEM) 63C is a member of the TMEM gene family 
and was recently linked to glomerular filtration barrier function and albuminuria. Its molecu-
lar function and expression regulation are largely unknown. Objective: In this study, we 
set out to characterize the regulating impact of microRNAs (miRNAs) such as miRNA-564 
(miR-564) on TMEM63C expression in renal cells. Also, we examined the influence of trans-
forming growth factor beta (TGF-ß) on TMEM63C expression and the potential impact of 
TMEM63C inhibition on epithelial-mesenchymal transition (EMT) in renal cells and on cell vi-
ability in human embryonic kidney 293 cells (HEK 293). Methods: Expression analyses were 
done using real-time PCR and Western blot. Dual luciferase assay was performed to determine 
the miRNA-mediated expression control. Cell viability was assessed via trypan blue exclusion 
staining. Results and Conclusions: MiR-564 reduced TMEM63C expression in HEK 293 and 
human podocytes (hPC). The treatment of renal cells with TGF-ß led to an increased expres-
sion of TMEM63C. Moreover, a reduced TMEM63C expression was associated with a changed 
ratio of EMT marker proteins such as α-smooth muscle actin versus E-cadherin in HEK 293 and 
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decreased nephrin expression in hPC. In addition, cell viability was reduced upon inhibition 
of TMEM63C expression in HEK 293. This study demonstrates first mechanisms involved in 
TMEM63C expression regulation and a link to EMT in renal cells. © 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Podocytes are terminally differentiated and highly specialized glomerular cells with a 
great importance for the glomerular filtration barrier (GFB) [1]. In this context, nephrin is 
known as an essential structural protein of the slit diaphragm and is considerably involved 
in the preservation of glomerular function as well as podocyte viability [2]. The injury or loss 
of podocytes leads to albuminuria and plays a pivotal role in several glomerular diseases 
including diabetic and non-diabetic kidney diseases [3, 4]. While albuminuria itself repre-
sents a marker of renal damage, it also has a direct pathogenic effect on renal tissue [5, 6]. 
Therefore, albuminuria is discussed as suitable therapeutic target for intervention to slow the 
progression of CKD [5].
Recently, a study identified transmembrane protein (TMEM) 63C  as a novel candidate 
for albuminuria development [7]. TMEM63C, a member of the TMEM  gene family, is expressed 
in the kidney, but also in many other tissues such as the cerebral cortex and endocrine tissues 
[7]. Schulz et al. [7] showed a loss of TMEM63C expression in podocytes of patients with focal 
segmental glomerulosclerosis. In addition, functional studies in zebra fish models suggested 
that TMEM63C could play an important role in GFB function [7]. Nevertheless, the biological 
function of TMEM63C and its expression regulation are widely unknown.
MicroRNAs (miRNAs) are short, non-coding RNAs consisting of 20–22 nucleotides, which 
are known to be influential regulators of post-transcriptional gene expression [8]. The regu-
lation and function of miRNAs are subject of current research. In this context, previous studies 
described a major influence of miRNAs on kidney diseases [8–10]. For example, miRNA-21 
(miR-21), miR-29, and miR-192 were found to play a pathophysiological role in renal fibrosis 
induced by transforming growth factor beta (TGF-β) [10]. Furthermore, the regulating effect 
of miRNAs becomes more important in cancer research. In this regard, the impact of several 
miRNAs, such as miR-21, miR-22, and miR-566, were described in the pathogenesis of renal 
cell cancer [11–13].
This study sets out to characterize the post-transcriptional regulation of TMEM63C 
expression by miRNAs including miR-30b and miR-564 in renal cells. Moreover, we analyzed 
the impact of small interfering RNA (siRNA)-mediated TMEM63C inhibition on cell viability. 
In addition, the effect of TGF-β on TMEM63C regulation and the impact of TMEM63C defi-
ciency on epithelial-mesenchymal transition (EMT) were analyzed in cell culture studies.
Methods
Cell Culture
Human podocytes (hPC; supplied by Dr. M. Saleem, University of Bristol, Bristol, UK) 
were cultured and differentiated as described previously [14]. For our investigations, we not 
only used hPC, but also human embryonic kidney 293 cells (HEK 293) due to its high trans-
fection efficiency and as suitable model to study epithelial characteristics in kidney cells. HEK 
293 (a kind gift of Prof. Dr. H. Fechner, Technical University of Berlin, Berlin, Germany) were 
cultured in DMEM enriched with 10% fetal bovine serum and 1% penicillin/streptomycin – 
all provided by Biochrom GmbH, Berlin, Germany. HEK 293 were grown in a humidified incu-
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bator at 37°C and with 5% CO2. Before transfection, HEK 293 and hPC were starved in fetal 
bovine serum-free DMEM or RPMI 1640, respectively. 200 nM of miR-30b, miR-564, or 
negative control (miRControl) miRNA mimic was used for miRNA transfection. For siRNA 
transfection, 200 nM of TMEM63C siRNAs (siTMEM63C) or scrambled control siRNAs 
(siControl) were deployed. Transfection was done by using LipofectamineTM 2000 (Invitrogen 
GmbH, Karlsruhe, Germany). The inhibitory effect of siTMEM63C was examined on mRNA 
and protein levels. For stimulation, hPC and HEK 293 were treated with 5 and 10 ng/mL 
TGF-β (eBioscience; Thermo Fisher Scientific GmbH, Waltham, MA, USA), respectively, for 
48 h. Transfection efficiency, determined by Dy547 transfection control (200 nmol/L; Fisher 
Scientific – Germany GmbH, Schwerte, Germany), was determined to be 25% in hPC [14] and 
62% in HEK 293.
Real-Time PCR
Analyses of mRNA expression were performed as described previously [14]. Specific 
TaqMan® Gene Expression Assays (Life Technologies GmbH, Darmstadt, Germany) were 
utilized for determination of TMEM63C, nephrin, α-smooth muscle actin (α-SMA), E-cadherin, 
and glyceraldehyde-3-phosphate dehydrogenase expression, following the manufacturer’s 
instructions. Real-time PCR was accomplished by means of 7500 Fast Real-time PCR System 
(Applied Biosystems, Carlsbad, CA, USA) using the following conditions: 50°C, 2 min; 95°C, 
20 s; 45 cycles 95°C, 3 s; 60°C, 30 s. The PCR primers used are shown in Table 1.
Western Blotting
Western blot analyses were done as described previously [15]. Specific antibodies against 
TMEM63C (Sigma-Aldrich Chemie GmbH, Munich, Germany) and glyceraldehyde-3-phosphate 
dehydrogenase (Calbiochem, Darmstadt, Germany) were used for detection. Blots were visu-
alized and quantified by using FUSION FX7 (Peqlab Biotechnologie GmbH, Erlangen, Deutschland) 
and Gel-Pro Analyser software version 4.0.00.001 (Media Cybernetics, Bethesda, MD, USA).
Dual Luciferase Activity Assay
For determination of dual luciferase activity, 2 × 104 HEK 293 were treated with miR-30b, 
miR-564, or miRControl in 96-well plates. Cells were co-transfected with aforementioned 
















Table 1. The primer sequences 
of real-time PCR
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miRNAs and 200 ng/mL dual luciferase reporter vector (3′UTR-TMEM63C vec) containing 
the 3′-untranslated region (3′UTR) of TMEM63C, a reporter vector (3′UTR-TMEM63C-mut 
vec) containing a mutated miRNA binding site in the 3′UTR of TMEM63C or a negative control 
vector (control vec), respectively (provided by GeneCopoeia, Inc., Rockville, MD, USA). After 
24 h, dual luciferase activity was analyzed by using a luciferase reporter assay (Promega 
GmbH, Mannheim, Germany) following the manufacturer’s protocol.
Cell Viability Assay
Cell viability was determined by a trypan blue staining assay. In brief, HEK 293 were 
seeded in 12-well plates and transfected with 200 nM siTMEM63C or siControl, as described 
previously. After 48 h, cells were removed from the wells using trypsin-EDTA and subse-
quently resuspended in fresh DMEM. 10 μL of cell suspension was mixed with 90 μL of trypan 
blue solution (Biochrom GmbH, Berlin, Germany). Eventually, living and trypan blue-stained 
dead cells were counted using a  C-Chip Neubauer improved hemocytometer chamber (Carl 
Roth GmbH & Co. KG., Karlsruhe, Germany).
Statistical Analysis
All results were represented as mean ± standard error the mean (SEM) and analyzed by 
Student’s t test or one-way ANOVA. A probability value (p) <0.05 was deemed as significant.
Results
Impact of Different miRNAs on TMEM63C Expression in HEK 293
First, we performed in silico analysis to identify potential miRNAs modulating TMEM63C 
expression on post-transcriptional level. In our analysis, we searched relevant databases, 
such as TargetScanHuman 7.1 (www.targetscan.org), miRDB (www.mirdb.org), and Diana 
Fig. 1. The impact of miR-30b and 
miR-564 on TMEM63C protein 
expression in HEK 293. The pro-
tein expression of TMEM63C in 
HEK 293 transfected with 
miR-30b, miR-564, or a negative 
control miRNA mimic (miRCon-
trol) is depicted. The expression 
was analyzed after 48 h. GAPDH 
was used for normalization. 
Shown is the mean ± SEM of at 
least 3 independent experiments. 
(*) p < 0.05. miR, miRNA; 
TMEM63C, transmembrane pro-
tein 63C; HEK 293, human embry-
onic kidney cells 293; GAPDH, 
glyceraldehyde-3-phosphate de-
hydrogenase.
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Tools (www.diana.imis.athena-innovation.gr). All of the abovementioned prediction tools 
revealed miR-30b and miR-564 as potential candidates for TMEM63C expression regulation 
via binding to the 3′UTR of TMEM63C mRNA. To examine the effect of the potential miRNA 
candidates on TMEM63C expression, we used respective miRNA mimics in our experiments. 
Next, we determined the influence of the aforementioned miRNAs on protein expression of 
TMEM63C in HEK 293. In our experiments, miR-30b and miR-564 led to a decreased protein 
generation of TMEM63C after 48 h (Fig. 1).
Fig. 2. The influence of miR-30b and miR-564 on luciferase activity in HEK 293. Shown is the luciferase ac-
tivity in HEK 293 transfected with (a) luciferase reporter construct containing 3′UTR of TMEM63C (3′UTR-
TMEM63C vec) and co-transfected with miR-30b, miR-564, or a negative control miRNA mimic (miRControl). 
For control, HEK 293 were co-transfected with (b) control vector (3′UTR-TMEM63C-mut vec), containing a 
mutated miRNA binding site in the 3′UTR of TMEM63C, and (c) a non-functional control vector (control vec), 
respectively. Firefly luciferase activity was determined 24 h after transfection and normalized against re-
nilla luciferase activity. In a, b, c, the mean ± SEM of at least 3 independent experiments is shown. (***) p < 
0.001. n.s., no significant difference; miR, miRNA; HEK 293, human embryonic kidney cells 293; 3′UTR, 3′-un-
translated region; TMEM63C, transmembrane protein 63C.
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Relative Luciferase Activity Measurement in HEK 293
Compared to controls, co-transfection of cells with the TMEM63C reporter vector and 
miR-564 led to a reduced luciferase activity, whereas co-transfection with a TMEM63C 
reporter vector including a mutated 3′UTR binding site and miR-564 exhibited no significant 
difference in luciferase activity (Fig. 2a, b). In contrast, co-treatment of HEK 293 with the 
reporter construct and miR-30b had no significant impact on luciferase activity in relation to 
controls (Fig. 2a).
Cell Viability of HEK 293 Was Decreased by siRNA-Mediated Inhibition of TMEM63C
After 48 h, we observed a significant reduction of TMEM63C protein expression in 
siTMEM63C-treated cells (Fig. 3a). Compared to controls, cell viability was also significantly 
reduced in siTMEM63C-transfected HEK 293 after 48 h (Fig. 3b).
TGF-β Stimulation Increased TMEM63C Protein Expression in HEK 293
We analyzed the impact of TGF-β stimulation on TMEM63C expression in HEK 293 after 
48 h. Compared to controls, treatment of the cells with TGF-β increased TMEM63C expression 
on protein level in a concentration-dependent manner (Fig. 4).
The Ratio of α-SMA versus E-Cadherin Was Affected by TMEM63C Expression
To investigate the impact of TMEM63C on EMT, we transfected HEK 293 with specific 
siRNAs against TMEM63C for 48 h and analyzed the ratio of α-SMA versus E-cadherin mRNA 
expression. Compared to controls, the ratio of α-SMA versus E-cadherin increased signifi-
cantly in siTMEM63C-treated cells (Fig. 5).
Fig. 3. The impact of TMEM63C inhibition on cell viability in HEK 293. HEK 293 were treated with specific 
siRNAs against TMEM63C (siTMEM63C) or scrambled control siRNAs (siControl) for 48 h. Shown is the (a) 
protein expression of TMEM63C and the (b) cell viability of HEK 293. The mean ± SEM of at least 3 indepen-
dent experiments is represented. (**) p < 0.01; (***) p < 0.001. TMEM63C, transmembrane protein 63C; HEK 
293, human embryonic kidney cells 293; siRNA, small interfering RNA.
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MiR-564 Decreased TMEM63C Expression in hPC
In addition to the experiments in HEK 293, we analyzed the impact of miR-564 on 
TMEM63C expression in hPC. Compared to controls, TMEM63C mRNA expression was signif-
icantly reduced in miR-564-transfected cells after 48 h (Fig. 6).
TGF-β Stimulation Increased TMEM63C Protein Expression in hPC
Subsequently, we investigated the impact of TGF-β on TMEM63C expression in hPC. 
Compared to controls, the treatment of the cells with 5 or 10 ng/mL TGF-β for 48 h increased 
TMEM63C expression on protein level in a concentration-dependent manner (Fig. 7).
Fig. 4. The effect of TGF-β stimu-
lation on TMEM63C protein ex-
pression in HEK 293. HEK 293 
were stimulated with 5 or 10 ng/
mL TGF-β for 48 h. TMEM63C was 
normalized against GAPDH. The 
mean ± SEM of at least 3 indepen-
dent experiments is shown. (*) p < 
0.05. n.s., no significant differ-
ence; TGF-β, transforming growth 
factor beta; TMEM63C, trans-
membrane protein 63C; HEK 293, 
human embryonic kidney cells 
293; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
Fig. 5. The effect of TMEM63C in-
hibition on α-SMA versus E-cad-
herin. HEK 293 were transfected 
with inhibitory siRNAs against 
TMEM63C (siTMEM63C) or non-
sense control siRNAs (siControl) 
for 48 h. Shown is the ratio of 
mRNA expression of α-SMA ver-
sus E-cadherin normalized 
against GAPDH. The mean ± SEM 
of at least 3 independent experi-
ments is represented. (***) p < 
0.001. TMEM63C, transmem-
brane protein 63C; α-SMA, 
α-smooth muscle actin; HEK 293, 
human embryonic kidney cells 
293; siRNA, small interfering 
RNA.
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Expression of Nephrin Was Reduced by siRNA-Mediated Inhibition of TMEM63C in hPC
Moreover, we studied the impact of TMEM63C expression on nephrin generation in hPC. 
Transfection of cells with TMEM63C-specific siRNAs led to a significant reduction of TMEM63C 
mRNA expression in hPC (Fig. 8a). Compared to controls, siRNA-mediated downregulation of 
TMEM63C was additionally associated with a significant decrease in nephrin expression on 
mRNA level after 48 h (Fig. 8b).
Fig. 6. The effect of miR-564 on 
TMEM63C mRNA expression in 
hPC. Shown is the expression of 
TMEM63C mRNA in hPC. Cells 
were transfected with miR-564 or 
a negative control miRNA mimic 
(miRControl). The expression 
was analyzed after 48 h. GAPDH 
was used for normalization. The 
mean ± SEM of at least 3 indepen-
dent experiments is shown. (***) 
p < 0.001. miR, miRNA; TMEM63C, 
transmembrane protein 63C; 
hPC, human podocytes; GAPDH, 
glyceraldehyde-3-phosphate de-
hydrogenase.
Fig. 7. The effect of TGF-β stimu-
lation on TMEM63C protein ex-
pression in hPC. hPC were stimu-
lated with 5 and 10 ng/mL TGF-β 
for 48 h, respectively. TMEM63C 
was normalized against GAPDH. 
The mean ± SEM of at least 3 inde-
pendent experiments is shown. 
(*) p < 0.05; (***) p < 0.001. TGF-β, 
transforming growth factor beta; 
TMEM63C, transmembrane pro-
tein 63C; hPC, human podocytes; 
GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase.
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Discussion
In this study, we identified TMEM63C as a direct target of miR-564. Furthermore, we 
showed an association between TMEM63C deficiency and reduced cell viability. Moreover, 
TMEM63C expression was found to be modulated by TGF-β stimulation in kidney cells. In 
addition to previous data [7], our data indicate that TMEM63C could be involved not only in 
GFB function but also in EMT.
Post-transcriptional Regulation of  TMEM63C Expression  by miR-564
We investigated the role of miRNAs in the regulation of TMEM63C expression. In a first 
step, we performed in silico analysis to identify potential miRNAs modulating TMEM63C 
expression on post-transcriptional level. In silico analysis is based on different computational 
algorithms, which are using different parameters to predict the probability of a functional 
miRNA binding site within a given mRNA target [16]. However, the characterization of miRNA-
mRNA interactions is challenging and difficult to predict [17]. For this reason, several miRNAs 
were predicted to regulate TMEM63C expression. For our in vitro experiments, we selected 
miR-30b and miR-564 as very likely candidates for TMEM63C regulation. Both were predicted 
by at least 3 different prediction tools. In this study, we showed a direct reduction of TMEM63C 
expression by miR-564 treatment in renal cells, while miR-30b inhibited TMEM63C possibly 
rather indirectly. Both miRNAs were shown to be expressed in kidney cells [18].
Some miRNAs are already known to be significant participants in renal pathologies, such 
as miR-21 or miR-192 in kidney fibrosis [10]. In addition, previous studies described a modu-
lating influence of miRNAs, such as miR-21, miR-22, or miR-566, in the genesis or prevention 
of renal cell cancer [11–13]. So far, miR-564 has not been identified in the context of renal 
pathologies, but various studies reported on the relevance of miR-564 and its function in 
different cancer biology. In this regard, miR-564 was demonstrated to induce cell apoptosis 
and to suppress cell proliferation in osteosarcoma cells by targeting protein kinase B [19]. 
Fig. 8. TMEM63C and nephrin expression in siTMEM63C-treated hPC. hPC were transfected with inhibitory 
siRNAs against TMEM63C (siTMEM63C) or nonsense control siRNAs (siControl) for 48 h. Shown is the mRNA 
expression of (a) TMEM63C and (b) nephrin. The mean ± SEM of at least 3 independent experiments is rep-
resented. (***) p < 0.001; (****) p < 0.0001. TMEM63C, transmembrane protein 63C; hPC, human podocytes; 
siRNA, small interfering RNA.
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Mutlu et al. [20] showed an inhibitory effect of miR-564 on cell proliferation in breast cancer 
cells due to suppression of phosphoinositide 3-kinase and mitogen-activated protein kinase. 
In addition, ectopic expression of miR-564 was described to stop EMT and reduce the 
migration and invasion of breast cancer cells [20]. In further studies, miR-564 was found to 
modulate TGF-β in different cell types [21, 22]. Jiang et al. [21] showed that miR-564 reduced 
TGF-β expression in glioblastoma cells. In another experimental setting, Xiao and Colleagues 
[22] presented an upregulation of miR-564 to be associated with an increased TGF-β 
expression in hypertrophic scars. So far, the role of miR-564 in the kidney, and especially in 
the context of renal pathologies, is unknown. However, miR-564 and its regulative function 
on TGF-β and EMT may not only be important in cancer, but could also be relevant in the 
modulation of renal fibrosis. In our study, miR-564 suppressed the expression of TMEM63C. 
For this reason, we investigated the effects of reduced TMEM63C expression on renal cells 
and studied the impact of TGF-β on TMEM63C expression.
Expression Regulation and Functional Effects of TMEM63C in HEK 293
Schulz et al. [7] showed the importance of TMEM63C expression for the maintenance of 
GFB in zebra fish models and demonstrated its potential relevance in patients with focal 
segmental glomerulosclerosis in translational studies. However, until now, the expression 
regulation of TMEM63C is widely unexplored. In our experiments, we used HEK 293 – due to 
its high transfection efficiency – to examine the expression regulation and impact of TMEM63C. 
The recent report already showed impaired cell viability due to suppression of TMEM63C in 
hPC [7]. In our study, we found downregulation of TMEM63C to be associated with reduced 
viability also in other renal cells (HEK 293). These results suggest that TMEM63C may have a 
beneficial effect on renal cell survival. Next, we analyzed the impact of TGF-β on TMEM63C 
expression. TGF-β is known as regulator and initiator of EMT and has been described as key 
mediator of glomerular and tubulointerstitial pathobiology in CKD [23, 24]. In CKD, TGF-β led 
to tubulointerstitial fibrosis and dysfunction of podocytes [25]. Previous studies showed that 
miR-564 is involved in the regulation of TGF-β [21, 22]. In this study, we found TGF-β to affect 
TMEM63C expression in a concentration-dependent manner. Further, we observed an inhib-
iting effect of miR-564 on TMEM63C generation. For this reason, we also studied the potential 
role of TMEM63C in EMT. In EMT, cells lose progressively their epithelial characteristics and 
acquire markers of mesenchymal phenotype [26]. Therefore, the ratio of epithelial and mesen-
chymal marker proteins is changed [27]. Typical epithelial markers are E-cadherin and fibro-
nectin, whereas typical mesenchymal proteins are N-cadherin, α-SMA, and vimentin [27]. HEK 
293 were shown to express both epithelial and mesenchymal marker proteins [28]. Therefore, 
we used these cells as suitable model to study the change of epithelial characteristics by altered 
TMEM63C expression. We found reduced TMEM63C expression to be associated with an 
increased ratio of α-SMA versus E-cadherin in HEK 293. This changing ratio of α-SMA versus 
E-cadherin is discussed as an indicator for tubular EMT [29]. However, the precise role of 
TMEM63C in EMT of renal tubular epithelial cells remains uncertain and should be investi-
gated in further experiments. In conclusion, we found siTMEM63C to reduce cell viability in 
HEK 293. In addition, we showed an association between reduced TMEM63C expression and 
a changing expression of proteins that are involved in EMT. Therefore, the increased expression 
of TMEM63C by TGF-β might reflect a potential protective mechanism of TMEM63C in renal 
cells under pathophysiological conditions, such as the development of renal fibrosis.
Expression Regulation and Functional Effects of TMEM63C in hPC
Similar to HEK 293, TGF-β treatment increased TMEM63C expression in a concentration-
dependent manner in hPC. Enhanced TGF-β concentration is associated with podocyte apop-
tosis and detachment from the glomerular basement membrane, EMT, and the development 
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of glomerulosclerosis [30]. For EMT studies in podocytes, it is important to consider that 
these cells have been described as atypical epithelial cells with a different expression of 
epithelial and mesenchymal proteins [31]. EMT in podocytes, also referred to as “podocyte 
disease transformation,” is associated with a decrease in proteins such as podocin, nephrin, 
and P-cadherin and an increase in α-SMA and N-cadherin [31, 32]. Moreover, Ghiggeri et al. 
[33] indicated that nephrin elimination may trigger EMT in hPC. We showed that reduced 
TMEM63C expression is associated with decreased generation of nephrin in hPC. These data 
support our suspicion that TMEM63C may play a potential role in modulation of EMT in renal 
cells. Further, nephrin is known as an essential structural protein of the slit diaphragm and is 
pivotal for the preservation of GFB function as well as podocyte viability [2]. Langham et al. 
[34] also showed reduced nephrin expression to be associated with proteinuria in relevant 
kidney diseases such as diabetic nephropathy. We found reduced nephrin expression by 
inhibiting TMEM63C. For this reason, the current data support our previous observations 
linking TMEM63C to the development of albuminuria [7]. Altogether, our results demon-
strated that TMEM63C is regulated by miR-564 and TGF-β in hPC and affects the expression 
of nephrin and could therefore influence the preservation of renal filter function.
Conclusion
In this study, we identified TMEM63C as a direct target of miR-564 in human renal cells. 
Moreover, the current study demonstrated that TMEM63C is regulated by TGF-β and could 
be involved in EMT. However, the effects of TMEM63C on EMT have not yet been clarified and 
should be investigated in further experiments. These experiments may include in vivo studies 
or at least studies in primary kidney cells, since experiments in immortalized cell lines, 
although important for mechanistic studies, should be viewed with some caution due to a 
potential permissive oncogenic phenotype for EMT studies [35]. Moreover, the role of EMT 
per se in the context of renal fibrosis has been questioned [36] and has been a matter of 
controversy [37]. Nevertheless, more recent studies indicated that at least partial EMT may 
be sufficient to promote renal fibrosis [38, 39] although evidence for human CKD is scant [37].
Our current results also support  recently reported findings linking TMEM63C-
expression to GFB function and albuminuria [7]. In the latter study,  downregulation of 
TMEM63C resulted in albuminuria in zebra fish models and reduced cell viability  of hPC, 
indicating a potential protective effect of TMEM63C for renal filter function [7]. In line with 
these findings, the current study showed siTMEM63C to reduce nephrin, a pivotal protein for 
the preservation of GFB function as well as podocyte viability [2]. Moreover, siRNA-mediated 
downregulation of TMEM63C led to a reduced cell viability of HEK 293. On the other hand, 
downregulation of TMEM63C in HEK 293 was linked to EMT by increasing the α-SMA/E-cadherin 
ratio and was thus associated with the activation of pro-fibrotic mechanisms [37]. In this 
regard, our finding demonstrating an upregulation of TMEM63C by TGF-β, which is a major 
driver of renal fibrosis, may reflect a counter-balancing mechanistic link between TMEM63C 
and TGF-β. Taken together, our data indicate that TMEM63C is not only linked to GFB function 
but may also be involved in EMT control. Therefore, TMEM63C is a novel functional candidate 
with potential impact for the development and progression of CKD.
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